Proton Therapy News and Research

RSS

Medicaid expansion increases cancer clinical trial participation

The Medicaid expansion under the Patient Protection and Affordable Care Act resulted in a 19% annual increase in Medicaid-insured cancer patients participating in publicly funded clinical trials, according to researchers from Fred Hutchinson Cancer Center, the SWOG Statistics and Data Management Center and Columbia University.

18 Aug 2023

Rutgers scientists discover first lipid vascular 'zip code' in the lungs

Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS), together with other collaborating groups, have discovered the first lipid vascular 'ZIP code' in the lungs.

16 Aug 2023

Proton radiotherapy used for the first time in Switzerland to treat esophageal tumor

A 67-year-old patient presenting with esophageal cancer was treated today at the Paul Scherrer Institute PSI with a form of radiation provided by protons, i.e. positively charged particles.

15 Aug 2023

Adenoid cystic carcinoma of the head and neck: A review of treatment strategies

A new editorial paper was published in Oncoscience (Volume 10) on June 28, 2023, entitled, "Adenoid cystic carcinoma of the head and neck – treatment strategies of a highly malignant tumor with variable localizations."

6 Aug 2023

First-in-human nanoparticle HIV vaccine induces broad and publicly targeted helper T cell responses

Researchers from Fred Hutchinson Cancer Center in Seattle, Scripps Research in La Jolla, California, IAVI and other collaborating institutions have characterized robust T-cell responses in volunteers participating in the IAVI G001 Phase 1 clinical trial to test the safety and immune response of a self-assembling nanoparticle HIV vaccine.

25 May 2023

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network and Fred Hutchinson Cancer Center.

16 May 2023

Clinical trial may set a new 'gold standard' for the treatment of childhood craniopharyngioma

St. Jude Children's Research Hospital is reporting phase 2 clinical trial results treating the brain tumor craniopharyngioma with proton therapy.

19 Apr 2023

HPV-related cancer diagnoses more common in AYA cancer survivors

A team of researchers at Huntsman Cancer Institute and the University of Utah (the U) found that human papillomavirus-related cancer diagnoses are more common in adolescent and young adults (AYAs) who have previously had cancer.

19 Apr 2023

Harnessing the forces of physics in the fight against cancer

"Physics against cancer" is a book about the origins of proton therapy at the Paul Scherrer Institute PSI.

13 Apr 2023

Improving cancer awareness among the rural American Indian communities

Phyllis Nassi, MSW, associate director of research and science, special populations, directs the American Indian program at Huntsman Cancer Institute and recently received the 2023 American Association for Cancer Research Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy.

6 Apr 2023

$3.2 million grant aids in the study of genetic testing approach to close racial disparity gaps in cancer care

With the aid of a near $3.2 million National Cancer Institute grant (R01CA277599) recently awarded, investigators from the state's leading cancer program, Rutgers Cancer Institute of New Jersey,  and Georgetown University's Lombardi Comprehensive Cancer Center, both NCI-designated Comprehensive Cancer Centers, will work to close racial disparity gaps in cancer care delivery by examining a novel approach to genetic testing and care based on community-identified needs.

30 Mar 2023

Drug combination may reduce the risk of prostate cancer progression, death

TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.

17 Mar 2023

What are the clinical considerations of proton radiotherapy for individuals with locally advancing breast cancer?

In a recent review published in Current Oncology, researchers highlighted the technical and clinical considerations for proton radiotherapy delivery for individuals with locally advancing breast malignancies.

1 Mar 2023

Analysis finds more than 100 new genetic risk factors strongly linked to colorectal cancer

A comprehensive analysis of more than 100,000 colorectal cancer (CRC) cases, led by researchers at the Fred Hutchinson Cancer Center in Seattle and 200 scientific collaborators worldwide, has identified more than 100 new genetic risk factors strongly linked with the disease.

20 Dec 2022

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

Investigators from Rutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Cancer Center and leading cancer program along with Tufts Medical Center in Boston, developed and validated the Advanced-stage Hodgkin lymphoma International Prognostication Index (A-HIPI).

12 Dec 2022

Study finds a positive impact of exercise on the gut microbiome of cancer patients

Regular physical activity can extend colorectal cancer patients' lives. In a first-ever study, scientists looked at the impact of exercise on the gut microbiome of cancer patients and reported a positive association.

14 Nov 2022

HPV vaccine rates in Utah increase by more than 16% among young men and women, CDC data reveals

When life should have been ripe with possibilities, Mandy Murry instead faced a devastating diagnosis. Murry was diagnosed with cervical cancer when she was 22.

4 Nov 2022

Researchers streamline way to manufacture CAR T-cells in just 24 hours

Researchers at University Hospitals (UH) Seidman Cancer Center and a biotech start-up company have developed a streamlined way to manufacture CAR T-cells for immunotherapy treatment in just 24 hours – an improvement over the team's previous benchmark of eight days and commercial suppliers that typically take three weeks.

25 Oct 2022

FLASH radiotherapy may hold promise as a potential treatment for tough-to-kill tumors

FLASH radiation treatment – which delivers therapeutic doses of radiation in a fraction of a second – may hold promise as a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests.

24 Oct 2022

Systematic differences in electronic health record data can negatively affect patient care

Patients from historically medically underserved groups, including patients of color and those who are Spanish-speaking, have less cancer family history information available to them. In addition, existing health records are less comprehensive, according to a study published October 4 in the Journal of the American Medical Association Network Open.

6 Oct 2022